The Pulmonary Fibrosis Foundation (PFF), the nation's leading pulmonary fibrosis (PF) research, education and advocacy ...

The global Progressive Pulmonary Fibrosis (PPF) Treatment Market is set to achieve a valuation of USD 3.72 million in 2023, ...

In cases of pulmonary fibrosis attributable to interstitial lung disease, whether the aetiology is known or unknown, the ...

London-based GSK is crossing the pond to form a new lung disease research collaboration with Boston scientists. | ...

AN INSIGHTFUL session on the future of lung transplantation presented at this year’s European Respiratory Society (ERS) ...

A higher abundance of monocyte-derived alveolar macrophages significantly correlated with worse lung fibrosis in RPRA ...

IPF is a chronic, progressive lung disease marked by lung tissue thickening and scarring, leading to reduced lung function. It is a specific type of interstitial lung disease, which includes various ...

Anti-fibrotic therapies, like Ofev and Genentech's Esbriet (pirfenidone), work by slowing the rate of fibrosis and are ...

Researchers from the Center for Regenerative Medicine (CReM) at Boston University and (BMC) have announced a new collaboration with the global biopharma company GSK to advance innovative research ...

When you can't breathe, the world stops,' a retired HPD officer said of his near-death battle with COVID-19. Fortunately, his world didn't stop; he discovered a new sense of purpose as a health ...

IPF treatment SM001-055 was generally safe and improved lung function, according to top-line data from a Phase 2a trial.